Boston, MA, 02/19/2014 – Pfizer Inc. (NYSE:PFE) is struggling to find new sources of growth given that its blockbuster drugs are losing patent protection. The company has had Viagra which is used for erectile dysfunction and Celebrex which is used for arthritis as two of its best selling drugs. However, things have change and if not, they are about to change in such a manner that PFE will be impacted by lower revenue unless fresh revenue sources are tapped. Currently analysts expect 2014 sales to slid 3 percent to just about $49.9 billion. It is good news for PFE investors that the company and Merck & Co., Inc. (NYSE:MRK) have announced collaboration towards the development of a new cancer drug. Shares of Pfizer Inc. (NYSE:PFE) lost 0.19 percent of their value to settle at $31.88 in the last session.
Groupon Inc (NASDAQ:GRPN) made a glaring error in its Presidents Day promotion whereby the online discounts and deals website referred to Alexander Hamilton as a “money-minded Commander-In-Chief,” president, that is. But those who know a bit of history understand that Hamilton was never president, instead, first Secretary of the Treasury. Now it is emerging that what Groupon did wasn’t an error anyway. Instead, it was a clever way to get people tweeting, talking and writing about Groupon which is good for marketing exposure, and that was undoubtedly achieved. Groupon Inc (NASDAQ:GRPN) lost 25 cents on each share in the last session to settle at $10.26 by bell time.
Galena Biopharma Inc (NASDAQ:GALE) is being investigated for possible breaches in relation to the stock promotion that the company reportedly sanctioned. Levi & Korsinsky is investigating GALE for any violation of fiduciary duties, more so in the line that whether a series of announcements which the company made relating to its operations, business and prospects were misleading or materially false. GALE admitted last Friday that it paid the DreamTeam Group, an investor relations firm to promote the company. The investigations seeks to unearth any foul play in much promotion and shareholders of Galena Biopharma Inc (NASDAQ:GALE) can pass their views regarding the matter to the investigating firm.